New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
19:08 EDTCODE, SNY, MANH, AMZN, WBSN, ISIS, UIS, KERX, BRCM, CHK, DLBOn The Fly: After Hours Movers
UP AFTER EARNINGS: Amazon (AMZN), up 9.2%... Dolby (DLB), up 4.2%... Unisys (UIS), up 10.9%... Manhattan Associates (MANH), up 3.6%... ALSO HIGHER: Chesapeake Energy (CHK), up 9.4% after CEO Aubrey McClendon announced he would retire April 1... ISIS Pharmaceuticals (ISIS), up 7.6% after the company announced it will receive a $25M milestone payment from Sanofi (SNY) following FDA approval of Kynamro... DOWN AFTER EARNINGS: Broadcom (BRCM), down 0.6%... Websense (WBSN), down 3.6%... Spansion (CODE), down 8.9%... ALSO LOWER: Keryx (KERX), down 2.7% after commencing the offering of $55M of common stock.
News For AMZN;DLB;UIS;MANH;CHK;ISIS;SNY;BRCM;WBSN;CODE;KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
March 23, 2015
09:11 EDTAMZNAmazon 'Unlocked' to give away paid apps, TechCrunch says
Subscribe for More Information
08:53 EDTAMZNAmazon VP and General Manager of Payments departs, TechCrunch says
Subscribe for More Information
08:13 EDTAMZNPendrell unit: Court rejects attempts to limit scope of DRM patents
ContentGuard Holdings, a subsidiary of Pendrell Corporation (PCO), announced that on Friday, March 20, Judge J. Rodney Gilstrap of the U.S. District Court for the Eastern District of Texas issued a 144 page Claim Construction Order in lawsuits ContentGuard filed against several companies who continue to use its patented Digital Rights Management solutions without a license, including Apple (AAPL), Amazon.com (AMZN), DirecTV (DTV), Google (GOOG), HTC, Huawei, Motorola Mobility and Samsung Electronics (SSNLF). In his order, Judge Gilstrap interpreted the language in ContentGuard’s patents in a manner that fully preserves the breadth of ContentGuard’s patented Digital Rights Management technologies. These technologies were developed to enable the distribution of digital media over the Internet and other networks, including cellular and satellite networks, and provide innovative solutions to problems that were once thought to be unsolvable. “We are very pleased with the Court’s ruling,” commented James Baker, ContentGuard’s Vice President for Licensing and Strategic Development. “We believe these claim constructions demonstrate that the online stores defendants provide for buying and renting DRM-protected movies, videos, books, and music and devices that play, run, display or print this DRM-protected content infringe ContentGuard’s pioneering DRM patents.”
07:04 EDTISISIsis Pharmaceuticals says ISIS-ANGPTL3Rx 'well tolerated' in Phase 1 study
Isis Pharmaceuticals announced positive results from a Phase 1 study with ISIS-ANGPTL3Rx. In this study, healthy volunteers treated with ISIS-ANGPTL3Rx achieved dose-dependent, statistically significant reductions in angiopoietin-like 3 of up to 93% with a mean reduction of up to 84% from baseline. In addition, statistically significant reductions from baseline in lipid parameters were observed, including up to 63% with a mean reduction of up to 49% in triglycerides and up to 46% with a mean reduction of up to 28% in total cholesterol. ANGPTL3 is a protein that acts as a key regulator of these blood lipids. These data were presented at the 83rd European Atherosclerosis Society in Glasgow, United Kingdom. The Phase 1 study of ISIS-ANGPTL3Rx was a blinded, placebo-controlled, dose-escalation study in healthy volunteers. The study was designed to assess the safety, tolerability and pharmacokinetics of ISIS-ANGPTL3Rx. ISIS-ANGPTL3Rx was evaluated in single and multiple doses ranging from 50 mg per week up to 400 mg per week for the single dose and 100 mg per week up to 400 mg per week for the multiple dose. In this study, ISIS-ANGPTL3Rx was generally well tolerated.
05:55 EDTAMZNStocks with implied volatility movement; AMZN CELG
Subscribe for More Information
March 20, 2015
11:45 EDTISISIsis Pharmaceuticals management to meet with Needham
Subscribe for More Information
10:43 EDTCHKStocks with call strike movement; CHK FCX
Chesapeake (CHK) July 16 call option implied volatility increased 2% to 50, Freeport McMoRan (FCX) August 20 call option implied volatility decreased 6% to 47 according to IVolatility.
09:45 EDTAMZNActive equity options trading on open
Subscribe for More Information
07:55 EDTKERXKeryx survey results positive, says Oppenheimer
After surveying 50 nephrologists/nurses/dietitians at U.S. dialysis clinics, Oppenheimer reported that dialysis providers it surveyed expect to prescribe Keryx's Auryxia in 11% of new starts and about 12% of switchers . As a result of this data points and other data from the survey, the firm expects Auryxia prescription trends to improve. It keeps an $18 price target and Outperform rating on the shares.
07:24 EDTBRCMBroadcom chip renews competition with in-house hardware makers, WSJ says
Subscribe for More Information
March 19, 2015
16:31 EDTAMZNAmazon Logistics UAS gets experimental airworthiness certificate
Subscribe for More Information
10:02 EDTCHKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:20 EDTCHKOn The Fly: Pre-market Movers
Subscribe for More Information
08:24 EDTCHKChesapeake downgraded at Sterne Agee
Subscribe for More Information
07:09 EDTSNYSanofi reports top-line results for Lyxumia for cardiovascular safety
Sanofi announced top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, which compared lixisenatide to placebo in a high-risk population of adults with type 2 diabetes evaluating cardiovascular safety. The study showed that lixisenatide was non-inferior, although not superior, to placebo for cardiovascular safety. The results will be included in the U.S. New Drug Application of lixisenatide, which is on track to be resubmitted to the FDA in Q3. Lixisenatide is not approved in the U.S.
06:20 EDTCHKChesapeake downgraded to Underperform from Neutral at Sterne Agee
05:53 EDTAMZNAmazon plans to shut down Shopify rival Amazon Webstore, Re/code reports
Amazon is planning to shut down Amazon Webstore, its competitor to Shopify and Bigcommerce, Re/code reports, citing sources. The company will allow its Webstore customers over a year to find a new vendor before the service is fully shut down, the sources say. Reference Link
05:30 EDTAMZNAmazon.com expands Prime Now delivery to Baltimore and Miami
Subscribe for More Information
05:30 EDTSNYSanofi reports lixisenatide was non-inferior, though not superior to placebo
Subscribe for More Information
March 18, 2015
09:32 EDTSNYMannKind faces cash shortfall if $100M debt not settled, TheStreet says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use